Clinical Trials Directory

Trials / Terminated

TerminatedNCT02216565

Embolectomy in Acute SYlvian Thrombosis in Refractory or Ineligible Patients to ALteplase

Benefits of the Endovascular Treatment in the Early Management of Proximal Sylvian Artery Thrombosis in Patients Refractory or Ineligible to Intravenous Fibrinolysis : a Multicenter Controled Randomized Trial

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
2 (actual)
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild · Network
Sex
All
Age
18 Years – 82 Years
Healthy volunteers
Not accepted

Summary

This trial aims at comparing two strategies currently used to address acute ischemic stroke of the middle cerebral artery : medical treatment without endovascular treatment on the one hand, and medical treatment plus endovascular treatment on the other hand. The efficiency of the strategies will be assessed in terms of early neurological clinical recovery. The study will focus on three particular situations : (1) tandem internal carotid and middle cerebral artery occlusion, (2) situations where patient cannot benefit from fibrinolysis because of high risk of haemorrhage, (3) situations where fibrinolysis is not recommended because of a delay superior to 4.5 hours. The hypothesis to be tested is that medical approach plus endovascular treatment is superior to medical treatment alone

Conditions

Interventions

TypeNameDescription
OTHERHospitalization in specialized neuro-vascular unit
DRUGAlteplase if patient is eligibleAlteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
OTHERSupportive careDrugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
PROCEDUREEndovascular treatmentRecanalization treatment (thrombectomy / intraarterial thrombolysis)

Timeline

Start date
2014-12-01
Primary completion
2015-08-31
Completion
2017-08-24
First posted
2014-08-15
Last updated
2017-12-05

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT02216565. Inclusion in this directory is not an endorsement.